稳定肾移植受者白蛋白尿与移植物衰竭、心血管事件及全因死亡:FAVORIT 试验队列分析
该研究为 FAVORIT 试验的事后纵向队列分析,纳入 3,511 例稳定肾移植受者,基线尿白蛋白肌酐比(ACR)中位 24 mg/g。多因素校正后,ACR 30-299 和 ≥300 mg/g 较 ACR<10 mg/g 与移植物衰竭、心血管事件及全因死亡风险独立相关。
要点
- 基线 ACR 升高是移植物衰竭的强独立危险因素,ACR≥300 mg/g 风险最高。
- ACR 30-299 mg/g 与心血管事件风险无显著独立关联。
- ACR≥300 mg/g 与心血管事件及全因死亡风险独立相关。
核心结论
- 在稳定肾移植受者中,基线 ACR 升高与移植物衰竭、心血管事件及全因死亡独立相关。
研究设计与样本
- FAVORIT 试验的事后纵向队列分析,纳入 30 个中心的稳定肾移植受者,共 3,511 例有完整数据。
主要发现
- 中位随访约 4 年,发生 282 例移植物衰竭、497 例心血管事件和 407 例死亡。
- ACR 30-299 mg/g 相比 ACR<10 mg/g,移植物衰竭 HR 3.40(95%CI 2.19-5.30),心血管事件 HR 1.25(95%CI 0.96-1.61),全因死亡 HR 1.65(95%CI 1.23-2.21)。
- ACR≥300 mg/g 相比 ACR<10 mg/g,移植物衰竭 HR 9.96(95%CI 6.35-15.62),心血管事件 HR 1.55(95%CI 1.13-2.11),全因死亡 HR 2.07(95%CI 1.46-2.94)。
临床怎么用
- 在稳定肾移植受者中,应关注基线 ACR 水平以识别移植物衰竭、心血管事件及死亡高风险患者。
局限性
- 缺乏排斥反应数据;仅单次 ACR 评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Cardiovascular disease (CVD) is common and overall graft survival is suboptimal among kidney transplant recipients. Although albuminuria is a known risk factor for adverse outcomes among persons with native chronic kidney disease, the relationship of albuminuria with cardiovascular and kidney outcomes in transplant recipients is uncertain. STUDY DESIGN: Post hoc longitudinal cohort analysis of the Folic Acid for Vascular Outcomes Reduction in Transplantation (FAVORIT) Trial. SETTING & PARTICIPANTS: Stable kidney transplant recipients with elevated homocysteine levels from 30 sites in the United States, Canada, and Brazil. PREDICTOR: Urine albumin-creatinine ratio (ACR) at randomization. OUTCOMES: Allograft failure, CVD, and all-cause death. ANALYTICAL APPROACH: Multivariable Cox models adjusted for age; sex; race; randomized treatment allocation; country; systolic and diastolic blood pressure; history of CVD, diabetes, and hypertension; smoking; cholesterol; body mass index; estimated glomerular filtration rate (eGFR); donor type; transplant vintage; medications; and immunosuppression. RESULTS: Among 3,511 participants with complete data, median ACR was 24 (Q1-Q3, 9-98) mg/g, mean eGFR was 49±18 (standard deviation) mL/min/1.73m2, mean age was 52±9 years, and median graft vintage was 4.1 (Q1-Q3, 1.7-7.4) years. There were 1,017 (29%) with ACR < 10mg/g, 912 (26%) with ACR of 10 to 29mg/g, 1,134 (32%) with ACR of 30 to 299mg/g, and 448 (13%) with ACR ≥ 300mg/g. During approximately 4 years, 282 allograft failure events, 497 CVD events, and 407 deaths occurred. Event rates were higher at both lower eGFRs and higher ACR. ACR of 30 to 299 and ≥300mg/g relative to ACR < 10mg/g were independently associated with graft failure (HRs of 3.40 [95% CI, 2.19-5.30] and 9.96 [95% CI, 6.35-15.62], respectively), CVD events (HRs of 1.25 [95% CI, 0.96-1.61] and 1.55 [95% CI, 1.13-2.11], respectively), and all-cause death (HRs of 1.65 [95% CI, 1.23-2.21] and 2.07 [95% CI, 1.46-2.94], respectively). LIMITATIONS: No data for rejection; single ACR assessment. CONCLUSIONS: In a large population of stable kidney transplant recipients, elevated baseline ACR is independently associated with allograft failure, CVD, and death. Future studies are needed to evaluate whether reducing albuminuria improves these outcomes.
引用
- Weiner DE, Park M, Tighiouart H, et al. Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. Am J Kidney Dis. 2018. PMID: 30037726. doi:10.1053/j.ajkd.2018.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。